Allison Bratzel
Stock Analyst at Piper Sandler
(4.90)
# 253
Out of 4,442 analysts
237
Total ratings
59.2%
Success rate
40%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HUMA Humacyte | Maintained: Hold | $1 | $0.7004 | +42.78% | 9 | Jun 18, 2026 | |
| ABVX ABIVAX Société Anonyme | Maintained: Buy | $165 | $98.43 | +67.63% | 11 | Jun 16, 2026 | |
| INCY Incyte | Maintained: Buy | $110 | $104.40 | +5.36% | 12 | Jun 9, 2026 | |
| TVTX Travere Therapeutics | Maintained: Buy | $49 | $55.95 | -12.42% | 20 | Jun 3, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Buy | $84 → $82 | $56.50 | +45.13% | 6 | May 21, 2026 | |
| RIGL Rigel Pharmaceuticals | Maintained: Hold | $40 | $35.61 | +12.33% | 9 | May 13, 2026 | |
| ARGX argenx SE | Maintained: Buy | $1,075 | $853.40 | +25.97% | 33 | May 11, 2026 | |
| ALXO ALX Oncology Holdings | Maintained: Buy | $4 | $1.76 | +127.27% | 6 | May 11, 2026 | |
| CDXS Codexis | Maintained: Buy | $9 | $2.39 | +276.57% | 11 | May 8, 2026 | |
| ENGN enGene Therapeutics | Downgraded: Hold | $26 → $4 | $1.71 | +133.92% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $68 | $28.76 | +136.44% | 6 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 | $36.31 | +43.21% | 8 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $6.18 | +158.90% | 8 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $100 | $75.99 | +31.60% | 13 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $1.10 | +263.64% | 17 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $26 → $30 | $11.81 | +154.02% | 5 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $4.54 | +164.32% | 5 | Apr 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $14 → $4 | $11.42 | -64.97% | 8 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $14.78 | +102.98% | 6 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 → $56 | $30.06 | +86.29% | 5 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $51 → $58 | $51.27 | +13.13% | 13 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3 → $0.5 | $0.008 | +6,150.00% | 5 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $17 | $5.63 | +201.95% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 | $32.21 | n/a | 6 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 → $20 | $8.79 | n/a | 6 | Mar 14, 2024 |
Humacyte
Jun 18, 2026
Maintained: Hold
Price Target: $1
Current: $0.7004
Upside: +42.78%
ABIVAX Société Anonyme
Jun 16, 2026
Maintained: Buy
Price Target: $165
Current: $98.43
Upside: +67.63%
Incyte
Jun 9, 2026
Maintained: Buy
Price Target: $110
Current: $104.40
Upside: +5.36%
Travere Therapeutics
Jun 3, 2026
Maintained: Buy
Price Target: $49
Current: $55.95
Upside: -12.42%
BioMarin Pharmaceutical
May 21, 2026
Maintained: Buy
Price Target: $84 → $82
Current: $56.50
Upside: +45.13%
Rigel Pharmaceuticals
May 13, 2026
Maintained: Hold
Price Target: $40
Current: $35.61
Upside: +12.33%
argenx SE
May 11, 2026
Maintained: Buy
Price Target: $1,075
Current: $853.40
Upside: +25.97%
ALX Oncology Holdings
May 11, 2026
Maintained: Buy
Price Target: $4
Current: $1.76
Upside: +127.27%
Codexis
May 8, 2026
Maintained: Buy
Price Target: $9
Current: $2.39
Upside: +276.57%
enGene Therapeutics
May 8, 2026
Downgraded: Hold
Price Target: $26 → $4
Current: $1.71
Upside: +133.92%
May 7, 2026
Maintained: Buy
Price Target: $68
Current: $28.76
Upside: +136.44%
May 7, 2026
Maintained: Buy
Price Target: $52
Current: $36.31
Upside: +43.21%
May 1, 2026
Maintained: Buy
Price Target: $16
Current: $6.18
Upside: +158.90%
Apr 24, 2026
Maintained: Buy
Price Target: $100
Current: $75.99
Upside: +31.60%
Apr 24, 2026
Maintained: Buy
Price Target: $4
Current: $1.10
Upside: +263.64%
Apr 22, 2026
Maintained: Buy
Price Target: $26 → $30
Current: $11.81
Upside: +154.02%
Apr 21, 2026
Maintained: Buy
Price Target: $12
Current: $4.54
Upside: +164.32%
Apr 10, 2026
Downgraded: Hold
Price Target: $14 → $4
Current: $11.42
Upside: -64.97%
Mar 24, 2026
Maintained: Buy
Price Target: $30
Current: $14.78
Upside: +102.98%
Mar 20, 2026
Maintained: Buy
Price Target: $42 → $56
Current: $30.06
Upside: +86.29%
Mar 4, 2026
Maintained: Buy
Price Target: $51 → $58
Current: $51.27
Upside: +13.13%
Jan 23, 2026
Downgraded: Hold
Price Target: $3 → $0.5
Current: $0.008
Upside: +6,150.00%
Jul 28, 2025
Maintained: Buy
Price Target: $20 → $17
Current: $5.63
Upside: +201.95%
Jul 18, 2024
Maintained: Buy
Price Target: $22
Current: $32.21
Upside: n/a
Mar 14, 2024
Upgraded: Buy
Price Target: $8 → $20
Current: $8.79
Upside: n/a